NOVA MOLECULAR INC has a total of 17 patent applications. Its first patent ever was published in 1996. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are ZINFANDEL PHARMACEUTICALS INC, CATALYST BIOMEDICA LTD and TC LAND EXPRESSION.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 5 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | Australia | 3 | |
#4 | Canada | 3 | |
#5 | United States | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Machines |
# | Technology | |
---|---|---|
#1 | Measuring microorganism processes | |
#2 | Therapeutic chemical compounds | |
#3 | Analysing materials | |
#4 | Medical preparations | |
#5 | Unspecified technologies |
# | Name | Total Patents |
---|---|---|
#1 | Schappert Keith | 12 |
#2 | Wiebusch Heiko | 8 |
#3 | Sevigny Pierre | 8 |
#4 | Poirier Judes | 5 |
Publication | Filing date | Title |
---|---|---|
WO0020634A1 | Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele | |
WO9966072A2 | Methods for treating a neurological disease by determining bche genotype | |
AU9454098A | Methods for increasing apoe levels for the treatment of neurodegenerative disease | |
US6251587B1 | Method for determining the prognosis of a patient with a neurological disease | |
US6022683A | Methods for assessing the prognosis of a patient with a neurodegenerative disease |